Abstract
Escalating global mental health demand exceeds existing clinical capacity. Scalable digital solutions will be essential to expand access to high-quality mental healthcare. This study evaluated the effectiveness of a digital intervention to alleviate mild, moderate and severe symptoms of generalized anxiety. This structured, evidence-based program combined an Artificial Intelligence (AI) driven conversational agent to deliver content with human clinical oversight and user support to maximize engagement and effectiveness. The digital intervention was compared to three propensity-matched real-world patient comparator groups: i) waiting control; ii) face-to-face cognitive behavioral therapy (CBT); and iii) remote typed-CBT. Endpoints for effectiveness, engagement, acceptability, and safety were collected before, during and after the intervention, and at one-month follow-up. Participants (n=299) used the program for a median of 6 hours over 53 days. There was a large clinically meaningful reduction in anxiety symptoms for the intervention group (per-protocol (n=169): change on GAD-7 = −7.4, d = 1.6; intention-to-treat (n=299): change on GAD-7 = −5.4, d = 1.1) that was statistically superior to the waiting control, non-inferior to human-delivered care, and was sustained at one-month follow-up. By combining AI and human support, the digital intervention achieved clinical outcomes comparable to human-delivered care while significantly reducing the required clinician time. These findings highlight the immense potential of technology to scale effective evidence-based mental healthcare, address unmet need, and ultimately impact quality of life and economic burden globally.
Competing Interest Statement
Chief Investigator (EMa) and other investigators (CEP, EMi, GW, MPE, EC, SL, AS, CH, JY, MB, LM, SM, RC, VT, AC, AW, AB) are employees of ieso Digital Health Limited (the company funding this research) or its subsidiaries. None of these authors had a direct financial incentive related to the results of this study or the publication of the manuscript.
Clinical Trial
ISRCTN ID: 52546704
Funding Statement
This research was funded by ieso Digital Health Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHS Research Ethics Committee (REC) West of Scotland REC 4 gave ethical approval for this research (IRAS ID: 327897)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Owing to the potential risk of patient identification, and following data privacy policies at ieso and DHC, individual-level data are not available. Aggregated data are available upon request, subject to a data-sharing agreement with ieso and DHC. Data requests should be sent to the corresponding author and will be responded to within 30 days.
